Drug Profile


Alternative Names: Arachidyl amido cholanoic acid; Aramchol

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galmed Medical Research
  • Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
  • Class Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Small molecules
  • Mechanism of Action ATP binding cassette transporter 1 stimulants; Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Lipodystrophy

Highest Development Phases

  • Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Jan 2017 Galmed Pharmaceuticals completes enrolment in the ARREST phase IIb trial for Non-alcoholic steatohepatitis in USA, Chile, Colombia, Mexico, Peru, France, Germany, Italy, Romania and China
  • 01 Dec 2016 Galmed Pharmaceuticals completes a pharmacokinetic study in healthy volunteers in USA (NCT02803996)
  • 22 Sep 2016 Galmed Pharmaceuticals and University of California at San Diego enter into a clinical trial agreement for a phase I/II trial in Non-alcoholic fatty liver disease (In adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top